

NCRI Renal Cancer Portfolio

RENAL CSG PORTFOLIO MAP		RENAL CANCER		
Turnour Type	Clear cell		Non-clear cell	Adrenal
Neoadjuvant				
Surgery	<p>EORTC 30073 CP SURTIME DA</p> <p>CARMENA DA</p>			
Adjuvant	<p>Photodynamic therapy T1a CA</p>		<p>Photodynamic therapy T1a CA</p>	<p>ADIUVO CA</p>
1 st line Metastatic	<p>NCRN544 CP DA</p> <p>STAR CP DA</p> <p>EORTC 30073 - SURTIME CP DA</p> <p>NCRN3427 PRINCIPAL CA DA</p> <p>CARMENA DA</p> <p>A-PREDICT** DP</p> <p>DIRECTS DA</p> <p>NCRN2511 CI</p> <p>PaZ02 CP</p> <p>HYPAZ** DP</p> <p>NCRN2888 CA</p> <p>NCRN396 YF Basket CA</p>		<p>NCRN3427 PRINCIPAL CP DP</p> <p>HYPAZ** OI</p> <p>NCRN2888 OI</p> <p>NCRN396 YF Basket OI</p>	
2 nd line Metastatic	<p>NCRN488** CI</p> <p>NCRN638** CI</p>			
3 rd line Metastatic	<p>NCRN488** CI</p> <p>NCRN638** CI</p>			
Non-Interventional	<p>SURAB CA</p> <p>Physical Activity remain for Cancer Survivors OA</p> <p>EuroTARGET** CA</p> <p>PCRN2263 OA</p> <p>SCOTRRCC CA</p>		<p>SURAB CA</p> <p>Physical Activity remain for Cancer Survivors OA</p> <p>EuroTARGET** CA</p> <p>PCRN2263 OA</p> <p>SCOTRRCC CA</p>	<p>Physical Activity remain for Cancer Survivors OA</p> <p>EuroTARGET** CA</p> <p>PCRN2263 OA</p>
<p>D : CSG-developed C : CSG-consulted O : Other A : Academically-sponsored P : Academic/Industry Partnership I : Industry-sponsored</p>				

NCRI Renal Cancer Portfolio

RENAL CSG PORTFOLIO MAP		RENAL CANCER		
Turnour Type	Clear cell		Non-clear cell	Adrenal
Neoadjuvant				
Surgery	EORTC 30073 CARMENA			
Adjuvant	Photodynamic therapy T1a **		Photodynamic therapy T1a **	ADIUVO
1 st line Metastatic	NCRN544 STAR EORTC 30073 - SURTIME NCRN3427 PRINCIPAL CARMENA A-PREDICT** DIRECTS NCRN2511 PaZ02 HYPAZ** NCRN2888 NCRN396 YF Basket		NCRN3427 PRINCIPAL HYPAZ** NCRN2888 NCRN396 YF Basket	
2 nd line Metastatic	SURAB Physical Activity remain for Cancer Survivors EuroTARGET** PCRN2263 SCOTRRCC			
3 rd line Metastatic	NCRN488 ** NCRN638**			
Non-Interventional	SURAB Physical Activity remain for Cancer Survivors EuroTARGET** PCRN2263 SCOTRRCC		SURAB Physical Activity remain for Cancer Survivors EuroTARGET** PCRN2263 SCOTRRCC	SURAB Physical Activity remain for Cancer Survivors EuroTARGET** PCRN2263
(D) : CSG-developed (C) : CSG-consulted (O) : Other (A) : Academically-sponsored (P) : Academic/Industry Partnership (I) : Industry-sponsored				

NCRI Renal Cancer Portfolio

RENAL CSG PORTFOLIO MAP		RENAL CANCER		
		YELLOW=OPEN/RECRUITING PURPLE=IN SET-UP/FUNDED CLEAR=MULTI-CSG STUDY; DASHED BORDER -IN SET-UP		
Turnour Type	Clear cell ** Involves tissue collection * Involves multiple tumour types		Non-clear cell	Adrenal
Neoadjuvant				
Surgery	<div style="border: 2px solid black; padding: 5px;"> C P EORTC 30073 SURTIME D A CARMENA </div>			
Adjuvant	C A Photodynamic therapy T1a **		C A Photodynamic therapy T1a **	C A ADIUVO
1 st line Metastatic	C P NCRN544 D A STAR C P EORTC 30073 - SURTIME C A NCRN3427 PRINCIPAL D A CARMENA D P A-PREDICT** D A DIRECTS C I NCRN2511 C P PaZ02 D P HYPAZ** C A NCRN2888 C A NCRN396 YF Basket		C P NCRN3427 PRINCIPAL O P HYPAZ** O I NCRN2888 O I NCRN396 YF Basket	
2 nd line Metastatic	C I NCRN488 ** C I NCRN638**			
3 rd line Metastatic				
Non-Interventional	C A SURAB O A Physical Activity remain for Cancer Survivors C A EuroTARGET** O A PCRN2263 C A SCOTRRCC		C A SURAB O A Physical Activity remain for Cancer Survivors C A EuroTARGET** O A PCRN2263 C A SCOTRRCC	O A Physical Activity remain for Cancer Survivors C A EuroTARGET** O A PCRN2263

D : CSG-developed
 C : CSG-consulted
 O : Other
 A : Academically-sponsored
 P : Academic/Industry Partnership
 I : Industry-sponsored



- More trials with TRANS-arms (surgeon led)
- Reinvigorate renal cancer surgical trials for the next decade
- But how...
- Multifactorial approach but...

NCRI/BAUS Fellow in Renal Cancer Surgery

- Are you a trainee (ideally post-CCT)?
- Are you interested in renal cancer?
- Are you (or do you think you might be) interested in clinical trials?
- Do you want to develop a niche?
- Then apply for the Renal Cancer CSG fellowship...



What will it do for you?

- Attendance at 2 renal cancer CSGs/yr
- Exposure to cutting edge renal cancer trials
- Networking with surgical and oncology leaders in the field
- Training via a CTU in trial development
- Direct involvement in renal cancer clinical trials, with a chance to shape the portfolio and develop your own trials



Interested?

- Contact:

- Mr Grant Stewart, Senior Lecturer Urological Surgery, University of Edinburgh

grant.stewart@ed.ac.uk

OR

- Dr James Larkin, Consultant Oncologist, Royal Marsden Hospital, London

james.larkin@rmh.nhs.uk

